


COMPANY PROFILE

STRATEC designs and manufactures fully automated analyzer systems and smart consumables on the basis of its own patented technologies for its partners in clinical diagnostics and the life sciences industry. The company also provides sample preparation solutions and integrated laboratory software for these applications.

STRATEC can draw on a wealth of experience and an extensive technology pool to offer its partners automation and instrumentation technologies and solutions, as well as software development and sample preparation services.

Its services include joint definition of specifications, the entire development process, production, quality assurance, and preparations for approval by the relevant authorities in the target markets. Both existing technologies and newly developed solutions are consistently adapted in terms of their design to conform to partners' own corporate design schemes.

SHARE CHART



SHAREHOLDER STRUCTURE

Investor group	Share
Fixed and family ownership (incl. investment companies)	41.47%
Treasury shares	0.06%
Institutional investors	36.72%
Retail investors including not identified institutional investors	21.75%
Total	100.00%

MANAGEMENT BOARD



Marcus Wolfinger



Dr. Robert Siegle



Dr. Claus Vielsack

SUPERVISORY BOARD

> Fred K. Brückner

> Rainer Baule

> Prof. Dr. Stefanie Remmele

STOCK FUNDAMENTALS

ISIN	DE000STRA555
WKN	STRA55
Symbol	SBS
Reuters Code	SBSG.DE
Branch	DAXsector All Pharma & Healthcare
Transparency level	Prime Standard
Market segment	Regulated Market
Type of shares	Registered Shares
Capital stock	11,962,495 Euro
No. of shares	11,962,495
Initial listing	Aug 25, 1998
Stock exchanges	Xetra; Frankfurt am Main and other regional exchanges in Germany

FINANCIAL CALENDAR

Nov 08, 2018	Publication quarterly statement (call-date Q3)
Nov 12, 2018	HSBC Healthcare Day Organized by: HSBC
Nov 14 - Nov 15, 2018	Jefferies London Healthcare Conference Organized by: Jefferies
Nov 27, 2018	German Equity Forum Organized by: Deutsche Börse - Analysts' Conference -

ANNUAL FIGURES

IFRS (in € million)	2013	2014	2015	2016	2017
Sales	128.0	144.9	146.9	184.9	209.8
EBIT	19.5	24.1	26.9	32.2	35.5
EBIT as % of sales	15.2	16.6	18.3	17.4	16.9
Consolidated net income	15.5	19.8	22.1	25.4	27.9
Basic earnings per share (in €)	1.32	1.68	1.87	2.12	2.33
Dividend per share (in €)	0.60	0.70	0.75	0.77	0.80
Total employees	546	544	583	976	1,086
Total assets	117.8	137.8	158.9	258.0	263.8
Equity ratio (in %)	82.5	81.3	82.0	55.2	59.8
Free cash flow	13.5	32.9	17.3	-	-

QUARTERLY FIGURES

IFRS (in € thousand)	2018		2017			2016	
	Q1	H1 ^{1,2}	Q1	H1 ^{1,2}	9M	Q1	H1
Sales	41,600	90,165	49,510	100,723	151,067	31,218	78,032
EBIT	4,293	8,846	6,870	12,816	23,973	4,530	12,616
EBIT as % of sales	10.3	9.8	13.9	12.7	15.9	14.5	16.2
Consolidated net income	3,533	7,240	5,369	9,902	18,627 ³	3,424	10,312
Basic earnings per share (in €)	0.30	0.61	0.45	0.84	1.57	0.29	0.87

¹ For comparison purposes, adjusted figures exclude amortizations resulting from purchase price allocations in the context of acquisitions, associated reorganization expenses, as well as other one-off items.

² Figures for H1 2018 in line with IFRS 9 and 15. The 2017 figures were not retroactively adjusted (modified retrospective method). Refer to the Management Report and the Notes for the impact of the first-time adoption of IFRS 9 and IFRS 15.

STRATEC Biomedical AG

Gewerbestr. 37
75217 Birkenfeld
Germany

Phone: +49 7082 7916-0
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com

Investor Relations

Phone: +49 7082 7916-6515
Fax: +49 7082 7916-9190
ir@stratec.com